Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Multi-centric Open Label Clinical Trial to Determine the Efficacy and Toxicity of Preoperative Chemotherapy With or Without Bevacizumab in Patients With Advanced Ovarian Cancer
Brief Summary: Recently results have shown that Bevacizumab is active both in monotherapy and in combination therapy in patients with ovarian cancer. One of our objectives is to evaluate whether the addition of neoadjuvant bevacizumab improves the response and whether this affects the evolution of patients.


Options:
A: Arm Label: 1 non-continuous; Type: OTHER; Interventions: Drug: Sunitinib | Arm Label: 2 continuous; Type: OTHER; Interventions: Drug: SUNITINIB | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): 1 non-continuous | Intervention Type: DRUG; Name: SUNITINIB; Assigned to Arm(s): 2 continuous
B: Arm Label: Paclitaxel & Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Paclitaxel & Carboplatin & Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Paclitaxel & Carboplatin & Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel & Carboplatin, Paclitaxel & Carboplatin & Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Paclitaxel & Carboplatin, Paclitaxel & Carboplatin & Bevacizumab
C: Arm Label: Arm I (placebo, paclitaxel, carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm II (placebo, paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm III (paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab)
D: Arm Label: Patupilone; Type: EXPERIMENTAL; Interventions: Drug: EPO906 (Patupilone) | Arm Label: doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: doxorubicin | Intervention Type: DRUG; Name: EPO906 (Patupilone); Assigned to Arm(s): Patupilone | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): doxorubicin

Answer: B